Archive · 3 Jul 2025
Alembic Pharmaceuticals US Arm Acquires Utility Therapeutics for $12M
Alembic Pharmaceuticals, a company that makes medicines, bought another company called Utility Therapeutics for $12 million.
Alembic wants to sell a medicine called Pivya in the US, which helps with urinary tract infections.
Pivya was approved by the FDA, a government agency, in April 2024.
This purchase will let Alembic sell special prescription medicines and grow their business in the United States.
Alembic plans to start selling Pivya in the US by the end of 2025.
Alembic Pharmaceuticals' US arm acquired Utility Therapeutics for $12 million.
The acquisition aims to strengthen Alembic's presence in the US market.
Alembic will commercialize Pivya (pivmethecillam) for urinary tract infections.
Pivya, approved by the FDA in April 2024, is a key product.
Pivya will be available in the US in Q4 2025.
- Who
- Alembic Pharmaceuticals, Inc., a subsidiary of Alembic Pharmaceuticals, acquired Utility Therapeutics Ltd.
- What
- Alembic Pharmaceuticals acquired Utility Therapeutics.
- When
- The acquisition was announced on Thursday, July 3, 2025.
- Where
- In the US.
- Why
- To strengthen Alembic's presence in the US market and to commercialize Pivya for urinary tract infections.
- Acquisition
- Utility Therapeutics Ltd
- Buyer
- Alembic Pharmaceuticals, Inc.
- Price
- $12 million
- Product
- Pivya (pivmethecillam)
- FDA Approval
- April 2024
- Commercial Launch
- Q4 2025